Implant system unit volume growth and ASP trends, particularly Nobel Biocare market share in premium segment versus Straumann and Dentsply
Digital dentistry adoption rates: intraoral scanner placements, treatment planning software subscriptions (recurring revenue visibility)
Orthodontic product mix shift toward clear aligners versus traditional brackets (competitive response to Align Technology's Invisalign dominance)
Geographic revenue mix, especially China dental market recovery and European practice consolidation trends
moderate - Dental procedures exhibit defensive characteristics as essential care (cleanings, restorations) continues through downturns, but elective procedures (implants, orthodontics) representing 40-50% of revenue are discretionary and defer during recessions. Practice capital equipment purchases (imaging systems, $50K-150K per unit) are highly cyclical and correlate with practice profitability and financing availability. Emerging market exposure adds GDP sensitivity as middle-class expansion drives dental care adoption.
Rising rates create headwinds through multiple channels: (1) dental practice financing costs increase, reducing capital equipment purchases and practice expansion; (2) consumer financing for elective procedures (implants averaging $3K-6K out-of-pocket) becomes less accessible; (3) valuation multiple compression as growth stocks re-rate. However, moderate debt/equity of 0.51x limits direct balance sheet impact. Falling rates stimulate practice investment cycles and patient procedure volumes.
Digital disruption and commoditization: Clear aligner technology (Align's Invisalign, SmileDirectClub direct-to-consumer) and AI-driven treatment planning reduce barriers to entry and compress pricing in orthodontics. 3D printing technology threatens traditional implant manufacturing moats.
Reimbursement pressure and insurance coverage shifts: Declining dental insurance coverage rates (48% of US population in 2026 vs 52% in 2020) and reduced benefits reduce patient affordability for premium procedures, pressuring volumes and mix toward lower-margin products.
Regulatory intensification: FDA scrutiny of dental devices, EU Medical Device Regulation compliance costs, and China NMPA approval timelines extend product development cycles and increase R&D burden.
value - Stock trades at 14.0x EV/EBITDA versus dental peers at 18-22x despite similar growth profiles, attracting value investors betting on operational improvement and multiple re-rating. Recent 47% three-month return suggests momentum investors entering on turnaround narrative. Low 1.5% ROE and 1.7% net margin indicate operational restructuring opportunity appealing to activist-oriented value funds. 5.0% FCF yield provides downside support.
Trend
-13.9% vs SMA 50 · +3.6% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $2.5B $2.5B–$2.5B | — | $0.71 | — | ±6% | High11 |
FY2025 | $2.6B $2.6B–$2.7B | ▲ +5.6% | $1.15 | ▲ +60.2% | ±1% | High11 |
FY2026(current) | $2.9B $2.8B–$2.9B | ▲ +8.2% | $1.43 | ▲ +24.8% | ±2% | High11 |
INSTITUTIONAL OWNERSHIP
NVST News
About
we know that dental professionals do more than create healthy, beautiful smiles—they create confidence. to achieve their goals, they need a champion. they need someone who will be there for them, side by side and end to end. at envista, we are uniquely positioned to be this champion. our differentiated combination of continuous improvement, a bias toward action and innovation, and a deep respect for the professionals we serve embolden us to champion dental professionals like no one else can. our comprehensive product portfolio covers an estimated 90% of dentists’ clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. we believe true champions lift each other up, and we are looking for new champions to join our team. if you believe, champions do more than win, they stand for something bigger, you can build a meaningful career at envista. if you believe champions work to be their best, help others be theirs, sho
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
NVST◀ | $23.22 | -0.25% | $3.8B | 56.2 | +832.1% | 172.8% | 1500 |
| $404.35 | -3.20% | $2.1T | 30.5 | +3296.8% | 4510.0% | 1500 | |
| $132.58 | -6.05% | $307.9B | 20.7 | -44.8% | 1012.0% | 1500 | |
| $88.38 | -2.58% | $303.7B | 13.6 | +318.8% | 1510.7% | 1500 | |
| $148.08 | -1.13% | $282.6B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $181.58 | -1.83% | $281.6B | 26.9 | +862.9% | 1745.9% | 1500 | |
| $183.40 | -0.23% | $256.1B | 16.8 | +213.3% | 1482.4% | 1500 | |
| Sector avg | — | -2.18% | — | 26.5 | +868.1% | 1856.9% | 1500 |